Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Acne vulgaris is a chronic inflammatory disease, mainly of the face, but also of the trunk. Acne may be caused by internal and external factors. Only a very small amount of data exists concerning truncal acne. The condition affects about 9% of the population worldwide, with 50% of subjects with facial acne also presenting with truncal acne. Until recently, clinicians frequently followed the same therapeutic approach as for facial acne, with treatment adherence remaining an issue.
This study assessed assessed the benefit of a cleansing gel containing salicylic acid 2%, zinc gluconate 0.2% and Lipo hydroxy acids (LHA) 0.05%, used daily for 84 days in mild to moderate truncal acne.
For this single center, open label, non-randomized exploratory study, 51 subjects with mild to moderate truncal acne were recruited. The study received ethics committee approval. All subjects provided written informed consent. The investigator evaluated the number of inflammatory, non-inflammatory and total lesions at Baseline, Day 42 and 84. Skin barrier function was appraised via the assessment of transepidermal water loss (TEWL) using a Tewameter® (Courage + Khazaka Electronic GmbH, Germany). Safety was assessed by considering the evaluation of clinical signs and reporting of symptoms, and local adverse reactions. Subjects were asked to gently massage the wet skin of the trunk with the product in the morning and evening for at least 30 seconds, and then thoroughly rinse with tempered water and pat dry.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Deep Cleansing Gel | Other | daily use |
| Measure | Description | Time Frame |
|---|---|---|
| Investigator global assessment | Scale 0=absent to 5=very serious | baseline |
| Investigator global assessment | Scale 0=absent to 5=very serious | Day 42 |
| Investigator global assessment | Scale 0=absent to 5=very serious | Day 84 |
| Measure | Description | Time Frame |
|---|---|---|
| inflammatory lesion count | count and percentage reduction | baseline |
| inflammatory lesion count | count and percentage reduction | Day 42 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
- None
Not provided
Not provided
Not provided
adult female or males with subjects with truncal acne
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Delphine Kerob, MD | La Roche-Posay Laboratoire Dermatologique | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CIDP | Rio de Janeiro | 20231-048 | Brazil |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36698447 | Derived | Towersey L, Correia P, Fajgenbaum Feiges M, Euzebio Goncalves Junior J, Sant'Anna B, Kerob D, Le Floc'h C. Assessment of the Benefit of a Deep Cleansing Gel Containing Salicylic Acid 2%, Zinc Gluconate 0.2% and Lipohydroxy Acids 0.05% in Patients with Mild to Moderate Truncal Acne: Results from an Exploratory Study. Clin Cosmet Investig Dermatol. 2023 Jan 18;16:119-123. doi: 10.2147/CCID.S394123. eCollection 2023. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000152 | Acne Vulgaris |
| ID | Term |
|---|---|
| D017486 | Acneiform Eruptions |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D012625 | Sebaceous Gland Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| inflammatory lesion count | count and percentage reduction | Day 84 |
| non-inflammatory lesion count | count and percentage reduction | baseline |
| non-inflammatory lesion count | count and percentage reduction | Day 42 |
| non-inflammatory lesion count | count and percentage reduction | Day 84 |
| total lesion count | count and percentage reduction | baseline |
| total lesion count | count and percentage reduction | Day 42 |
| total lesion count | count and percentage reduction | Day 84 |
| acne severity | scale 0=absent to 5=very severe | baseline |
| acne severity | scale 0=absent to 5=very severe | Day 42 |
| acne severity | scale 0=absent to 5=very severe | Day 84 |
| transepidermal water loss | tewameter assessment | baseline |
| transepidermal water loss | tewameter assessment | Day 42 |
| transepidermal water loss | tewameter assessment | Day 84 |
| clinical safety | assessment of clinical signs symptoms and adverse events | baseline |
| clinical safety | assessment of clinical signs symptoms and adverse events | Day 42 |
| clinical safety | assessment of clinical signs symptoms and adverse events | Day 84 |
| subject efficacy perception | scale 0=none to 5= very good | Day 42 |
| subject efficacy perception | scale 0=none to 5= very good | Day 84 |
| subject product perception | sacle 0=bad to 5 very good | Day 84 |